Blinatumomab improves event-free survival in children with high-risk B-cell ALL
Blinatumomab is associated with significantly higher event-free survival among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), according to a study published in the Sept. 17 issue of the New England Journal of Medicine.
<p>Blinatumomab is associated with significantly higher event-free survival among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), according to a study published in the Sept. 17 issue of the New England Journal of Medicine.</p>